Prevalence of pre-existing direct-acting antiviral agents resistance-associated variants in genotype 1 HCV/HIV co-infected patients / 上海交通大学学报(医学版)
Journal of Shanghai Jiaotong University(Medical Science)
;
(12): 411-415, 2018.
Article
in Chinese
| WPRIM
| ID: wpr-843728
ABSTRACT
Objective:
To investigate the prevalence of pre-existing direct-acting antiviral agents (DAAs) resistance associated variants (RAVs) in genotype 1 hepatitis C virus (HCV)/ human immunodeficiency virus (HIV) co-infected patients.Methods:
All NS3 and NS5B HCV sequences in genotype 1 HCV/HIV co-infected patients were retrieved from NCBI GenBank database. And sequences were aligned and analyzed using software MEGA 5.0.Results:
In total, the overall prevalence of DAAs RAVs in NS3 region was high (26.06% and 38. 18%, respectively), no matter in genotype 1a or genotype 1b. In genotype 1a, the high prevalence of RAVs mainly presented in the position Q80 (8.45%). In genotype 1b, S122 RAV was most observed (36.36%). It is worth noting that, RAVs in NS5B region were rare observed (0.77%) in this study, especially as no RAV was detected in any sequence of genotype 1a patients.Conclusion:
The prevalence of pre-existing RAVs is high in NS3 region but rare in NS5B region in HCV/HIV co-infected patients, suggesting that NS5B inhibitors based combination regions are a better choice for HCV/HIV co-infected patients.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Prevalence study
/
Risk factors
Language:
Chinese
Journal:
Journal of Shanghai Jiaotong University(Medical Science)
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS